Gene therapy for cancer: present status and future perspectiveReport as inadecuate




Gene therapy for cancer: present status and future perspective - Download this document for free, or read online. Document in PDF available to download.

Molecular and Cellular Therapies

, 2:27

First Online: 10 September 2014Received: 09 April 2014Accepted: 22 August 2014DOI: 10.1186-2052-8426-2-27

Cite this article as: Amer, M.H. Mol and Cell Ther 2014 2: 27. doi:10.1186-2052-8426-2-27

Abstract

Advancements in human genomics over the last two decades have shown that cancer is mediated by somatic aberration in the host genome. This discovery has incited enthusiasm among cancer researchers; many now use therapeutic approaches in genetic manipulation to improve cancer regression and find a potential cure for the disease. Such gene therapy includes transferring genetic material into a host cell through viral or bacterial and non-viral vectors, immunomodulation of tumor cells or the host immune system, and manipulation of the tumor microenvironment, to reduce tumor vasculature or to increase tumor antigenicity for better recognition by the host immune system. Overall, modest success has been achieved with relatively minimal side effects. Previous approaches to cancer treatment, such as retrovirus integration into the host genome with the risk of mutagenesis and second malignancies, immunogenicity against the virus and-or tumor, and resistance to treatment with disease relapse, have markedly decreased with the new generation of viral and non-viral vectors. Several tumor-specific antibodies and genetically modified immune cells and vaccines have been developed, yet few are presently commercially available, while many others are still ongoing in clinical trials. It is anticipated that gene therapy will play an important role in future cancer therapy as part of a multimodality treatment, in combination with, or following other forms of cancer therapy, such as surgery, radiation and chemotherapy. The type and mode of gene therapy will be determined based on an individual’s genomic constituents, as well as his or her tumor specifics, genetics, and host immune status, to design a multimodality treatment that is unique to each individual’s specific needs.

KeywordsAdenoviruses Clinical trials Electroporation Gene silencing Gene transfer technique Immunomodulation Molecular targeted therapy Oncolytic viruses Retroviruses Suicide transgenes AbbreviationsAPCsAntigen-presenting cells

CEACarcinoembryonic antigen

DNADeoxyribonucleic acid

DTA-H19Corynebacterium diphtheriae toxin-A chain

EGFREpidermal growth factor receptor

Fox3Forkhead box 03 transcription factor protein

FDAThe Food and Drug Administration in the United States

GDEPTGene directed enzyme prodrug therapy

GM-CSFGranulocyte macrophage colony stimulating factor

HER-2-neuHuman epidermal growth factor receptor-2

HIVHuman immunodeficiency virus infection

hTERTHuman telomerase reverse transcriptase

IDOIndoleamine-2,3-dioxygenase

MHCMajor histocompatibility complex

MDR1Multidrug-resistant protein-1

mRNAMessenger-RNA

NKNatural killer cell lymphocytes

PSAProstatic acid phosphatase antigen

RISCRibonucleic acid induced silencing complex

RNARibonucleic acid

RNAiRibonucleic acid interference

siRNASmall interfering double-stranded RNA

TAAsTumor-associated antigens

TCRT cell antigen receptor

TRICOMMultiple T-cell costimulatory molecules

VEGF-AVascular endothelial growth factor A receptor.

Electronic supplementary materialThe online version of this article doi:10.1186-2052-8426-2-27 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Magid H Amer

Source: https://link.springer.com/







Related documents